Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote FOR All Proxy Proposals at the Special Meeting to be held on January 10, 2024

NEW YORK, Jan. 2, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare...

Related Keywords

New York ,United States ,Anthony Marciano ,Mike Moyer ,Prnewswire Seelos Therapeutics Inc ,Nasdaq ,Seelos Therapeutics Inc ,Lifesci Advisors ,Institutional Shareholder Services ,Morrow Sodali ,Exchange Commission ,Special Meeting ,Seelos Board ,Proxy Statement ,Acute Suicidal Ideation ,Major Depressive Disorder ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Sci Advisors ,Markets ,